Unknown

Dataset Information

0

Generating and measuring effective vaccine-elicited HIV-specific CD8 + T cell responses.


ABSTRACT:

Purpose of review

There is growing consensus that eliciting CD8 + T cells in addition to antibodies may be required for an effective HIV vaccine for both prevention and cure. Here, we review key qualities of vaccine-elicited CD8 + T cells as well as major CD8 + T cell-based delivery platforms used in recent HIV vaccine clinical trials.

Recent findings

Much progress has been made in improving HIV immunogen design and delivery platforms to optimize CD8 + T cell responses. With regards to viral vectors, recent trials have tested newer chimp and human adenovirus vectors as well as a CMV vector. DNA vaccine immunogenicity has been increased by delivering the vaccines by electroporation and together with adjuvants as well as administering them as part of a heterologous regimen. In preclinical models, self-amplifying RNA vaccines can generate durable tissue-based CD8 + T cells. While it may be beneficial for HIV vaccines to recapitulate the functional and phenotypic features of HIV-specific CD8 + T cells isolated from elite controllers, most of these features are not routinely measured in HIV vaccine clinical trials.

Summary

Identifying a vaccine capable of generating durable T cell responses that target mutationally vulnerable epitopes and that can rapidly intercept infecting or rebounding virus remains a challenge for HIV. Comprehensive assessment of HIV vaccine-elicited CD8 + T cells, as well as comparisons between different vaccine platforms, will be critical to advance our understanding of how to design better CD8 + T cell-based vaccines for HIV.

SUBMITTER: Borgo GM 

PROVIDER: S-EPMC10552829 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Generating and measuring effective vaccine-elicited HIV-specific CD8 + T cell responses.

Borgo Gina M GM   Rutishauser Rachel L RL  

Current opinion in HIV and AIDS 20230920 6


<h4>Purpose of review</h4>There is growing consensus that eliciting CD8 + T cells in addition to antibodies may be required for an effective HIV vaccine for both prevention and cure. Here, we review key qualities of vaccine-elicited CD8 + T cells as well as major CD8 + T cell-based delivery platforms used in recent HIV vaccine clinical trials.<h4>Recent findings</h4>Much progress has been made in improving HIV immunogen design and delivery platforms to optimize CD8 + T cell responses. With regar  ...[more]

Similar Datasets

| S-EPMC5580930 | biostudies-literature
| S-EPMC3196391 | biostudies-literature
| S-EPMC5295143 | biostudies-literature
| S-EPMC8136468 | biostudies-literature
| S-EPMC3900398 | biostudies-literature
| S-EPMC4376642 | biostudies-literature
| S-EPMC9577258 | biostudies-literature
| S-EPMC2569185 | biostudies-literature
| S-EPMC5378478 | biostudies-literature
| S-EPMC5821448 | biostudies-literature